Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]

Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY]

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ixoberogene soroparvovec (Primary) ; Aflibercept
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Acronyms INFINITY
  • Sponsors Adverum Biotechnologies

Most Recent Events

  • 06 Aug 2023 Status changed from active, no longer recruiting to completed.
  • 04 Nov 2021 According to an Adverum Biotechnologies media release, data from this study will be presentation at the American Academy of Ophthalmology Annual Meeting (AAO 2021), November 12-15, 2021.
  • 04 Nov 2021 According to an Adverum Biotechnologies media release, data from the trial were presented at the American Society of Retina Specialists (ASRS) 39th Annual Scientific Meeting, 2021.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top